Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wright Implies First-To-Market Advantage Over Hip Resurfacing Rivals

This article was originally published in The Gray Sheet

Executive Summary

British orthopedic manufacturers Smith & Nephew and Corin Group likely will need to gather additional U.S. data on their respective hip resurfacing products to earn PMA approval, Wright Medical claims

You may also be interested in...



Wright Medical ramps up reps

Wright's commissioned independent sales force likely will grow by 20% to 380 reps, the company says during Q4 earnings call. The larger sales force will help launch Wright's Conserve Plus femoral surface replacement system after approval. The firm awaits a PMA panel appointment; FDA nixed April as an option, leaving potential dates in July and October. Despite the uncertainty, Wright anticipates being first to market in the U.S. (1"The Gray Sheet" Dec. 13, 2004, p. 15). The manufacturer recorded sales of $77.7 mil. for Q4, up 13%. Overall, in 2004, sales increased 20% to $297.5 mil. The company anticipates sales exceeding $333 mil. in 2005...

New Hip Replacement Reflects Well On Smith & Nephew Sales Team – CEO

Smith & Nephew says the launch of its Reflection hip replacement implant in January has given its sales personnel increased standing with doctors to market the firm's full suite of hip products

Wright Medical ramps up reps

Wright's commissioned independent sales force likely will grow by 20% to 380 reps, the company says during Q4 earnings call. The larger sales force will help launch Wright's Conserve Plus femoral surface replacement system after approval. The firm awaits a PMA panel appointment; FDA nixed April as an option, leaving potential dates in July and October. Despite the uncertainty, Wright anticipates being first to market in the U.S. (1"The Gray Sheet" Dec. 13, 2004, p. 15). The manufacturer recorded sales of $77.7 mil. for Q4, up 13%. Overall, in 2004, sales increased 20% to $297.5 mil. The company anticipates sales exceeding $333 mil. in 2005...

Related Content

UsernamePublicRestriction

Register

MT021323

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel